The Duke ACTIV-4 hospital medicine research team was invited to speak at the NIH funded, ACTIV-4A international monthly meeting hosted by New York University (NYU).
ACTIV-4A is a multi-center international trial evaluating therapeutics to treat thrombo-inflammation caused by COVID-19. There are participating hospitals throughout the United States, Mexico, Brazil and Europe. Duke University Health System remains the top enrolling site, which is ran out of the Duke Hospital Medicine Research Program (HMRP) led by Lana Wahid, MD. Duke was recognized as a “Site of Excellence” and invited to share current strategies on enlisting and retaining patients.
On April 06, 2022, Jason Bissey (Clinical Research Nurse Coordinator) and Oluwayemisi Mohammed (Senior Research Coordinator) presented “Contributors to ACTIV-4A Clinical Trial Success at Duke Health System” to over 200 attendees. Jason was the lead speaker and shared their best practices on the different steps involved in clinical trials. Jason and Yemisi have been instrumental in working with the Duke Office of Clinical Research (DOCR) Maestro analyst team to develop a comprehensive screening tool within EPIC that allows for rapid screening of the large volume of COVID patients, which was especially helpful during peak COVID admissions.
"[Duke's] hospital medicine research team’s hard work, selfless contribution and dedication is leading enrollment throughout the world in this clinical trial."
“I am privileged to be a part of such an amazing team," says Wahid. "The hospital medicine research team’s hard work, selfless contribution and dedication is leading enrollment throughout the world in this clinical trial. Our COVID-19 nurses, clinicians, phlebotomists, therapist, lab, pharmacists and environmental services have all made a huge impact in putting Duke at the forefront of advancing the science of COVID-19."